MarketPeel
Insider Trading Intelligence
BP

Brian Piekos

KALV
CHIEF FINANCIAL OFFICER · KALVISTA PHARMACEUTICALS, INC. · CIK 0001815308
FILING MIX · LIFETIME43%/57%
BUYS
9
SELLS
12
TOTAL VALUE
$165.2K
COMPANIES
2
ACTIVE SINCE
Jun 2023
HOLDINGS NOW
43,225
AVG SELL PX
$17.23
TRADE KIND
SHOWING 21 / 21
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 9 pending
Forward-return performance of every backtestable P/S trade by Brian Piekos, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+33.33%+1.08%+0.95%+0.14%+2.47%
14d3+0.00%+22.50%+1.03%+21.47%+23.97%
30d3+0.00%+19.62%+1.34%+18.28%+14.95%
60d3+0.00%+23.03%+4.66%+19.19%+19.19%
90d3(1 pending)+0.00%+44.32%+2.04%+14.42%+14.42%
180d3(2 pending)+0.00%+100.52%
1y3(3 pending)
2y3(3 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KALV · 0 shares · as of Jun 11, 2026
025,00050,00075,000100,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 9 buys / 12 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
21,6610Jun 11, 2026Jun 11, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
100,0000Jun 11, 2026Jun 11, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
55,0000Jun 11, 2026Jun 11, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
93,7500Jun 11, 2026Jun 11, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,489$26.78$39.9K21,661May 22, 2026May 26, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
5,00023,150May 21, 2026May 26, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
5,00055,000May 21, 2026May 26, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,862$20.22$37.6K18,150Apr 17, 2026Apr 20, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
6,25020,012Apr 16, 2026Apr 20, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
6,25093,750Apr 16, 2026Apr 20, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,767$15.57$27.5K13,762Feb 23, 2026Feb 24, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
5,00060,000Feb 21, 2026Feb 24, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
5,00015,529Feb 21, 2026Feb 24, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,000100,000Jan 16, 2026Jan 21, 2026View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
4,471$13.45$60.1K10,529Nov 24, 2025Nov 26, 2025View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
15,00015,000Nov 21, 2025Nov 26, 2025View →
KALV
KALVISTA PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
15,00065,000Nov 21, 2025Nov 26, 2025View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
80,00080,000Feb 21, 2025Feb 25, 2025View →
KALV
KALVISTA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,000100,000Sep 9, 2024Sep 11, 2024View →
ELTX
ELICIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
43,22543,225Feb 1, 2024Feb 5, 2024View →
ELTX
ELICIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,48475,484Jun 1, 2023Jun 5, 2023View →
Other insiders · KALV
Loading peer insiders…
About this filer
CIK 0001815308
ROLE
Chief Financial Officer
PRIMARY
KALV
COMPANIES
2
ACTIVE SINCE
Jun 2023
MARKETPEEL · /INSIDER/0001815308DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback